CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology 2024, 21: 1089-1108. PMID: 39134804, PMCID: PMC11442786, DOI: 10.1038/s41423-024-01207-0.Peer-Reviewed Original ResearchCAR-natural killerCAR-T cellsCAR-TSolid tumorsHematologic malignanciesCell therapyChimeric antigen receptor (CAR)-T cell therapyImmuno-suppressive tumor microenvironmentCAR-T cell therapyCellular cancer immunotherapyRelapsed/refractory hematologic malignanciesCAR-NK cellsTumor traffickingAdoptive immunotherapyCell immunotherapyCellular immunotherapyCancer immunotherapyImmunotherapeutic approachesHLA compatibilityTumor microenvironmentAdult patientsImmunotherapyCombat cancerTumorMalignancyImmunometabolism of CD8+ T cell differentiation in cancer
Shi H, Chen S, Chi H. Immunometabolism of CD8+ T cell differentiation in cancer. Trends In Cancer 2024, 10: 610-626. PMID: 38693002, PMCID: PMC11342304, DOI: 10.1016/j.trecan.2024.03.010.Peer-Reviewed Original ResearchCD8<sup>+</sup> cytotoxic T lymphocytesT cell receptorImmune signalingCD8+ T cell differentiationMediators of tumor immunityTumor antigen recognitionCytotoxic T lymphocytesT cell differentiationTumor-immune interactionsTumor immunityNovel immunotherapiesT lymphocytesIntracellular metabolic pathwaysCo-stimulationAntigen recognitionMetabolic programmingDesign novel immunotherapiesImmunotherapyCentral mediatorsMetabolic landscapePost-transcriptional mechanismsTumorBidirectional regulationSignaling eventsMetabolic processes